Jilted for someone younger

Biopharmaceutical CEOs worried that institutional investors will never again hunger to have biotech stocks in their portfolios can take some indirect comfort from the experience of Accel Partners in raising its new venture fund.

But it's the kind of comfort that can best be described as "cold," since those same institutions aren't anywhere near ready to resume their support of publicly held companies.